# Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit

> **NCT00637611** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 1010 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** Fexofenadine HCl

## Key facts

- **NCT ID:** NCT00637611
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2003-04
- **Target enrollment:** 1010 (ACTUAL)
- **Last updated:** 2011-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00637611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00637611, "Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00637611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*